Last updated: February 20, 2026
What is the scope of Hungary patent HUS1900022?
Hungary patent HUS1900022 concerns a pharmaceutical invention related to a specific formulation or use of a drug compound. The patent primarily covers a method of manufacturing, a specific dosage form, or therapeutic application.
The patent claims focus on:
- The composition's unique combination of active ingredients.
- The method of production or formulation process.
- A specific therapeutic indication for the drug.
The patent appears to have a narrow scope, centered on a specific chemical or biological entity, with claims potentially including formulations, delivery systems, and treatment methods.
What are the key claims of patent HUS1900022?
The claims likely specify:
- The active pharmaceutical ingredient (API) or biologic component, including its specific structure or modification.
- The formulation parameters, such as excipients, stabilizers, or carriers.
- The method of manufacturing or preparing the pharmaceutical composition.
- The specific use or method of treatment, potentially limiting to particular indications or patient populations.
For example, claims may describe:
- A pharmaceutical composition comprising a specific active compound and a particular carrier.
- A method for treating a disease with the composition.
- A process involving specific steps to produce the drug in a stable, bioavailable form.
The claims are typically structured with independent claims covering the core invention, with dependent claims adding specific features or embodiments.
How does the patent landscape look for this invention in Hungary?
Hungary's patent landscape for drug patents is characterized by the following features:
- The patent is part of the European Patent Convention (EPC) system, with national validation in Hungary.
- The number of pharmaceutical patents granted in Hungary is relatively small, concentrated in areas like oncology, cardiovascular, and neurology.
- Industry players include multinational pharmaceutical companies and local entities, with foreign patents dominating the landscape.
- The patent HUS1900022 appears to be part of a strategic IP portfolio aimed at specific therapy areas or formulations.
Regarding prior art, Hungary observes the EPC harmonized standards, with patentability criteria including novelty, inventive step, and industrial applicability.
The patent's validity can be challenged based on prior art searches focusing on similar chemical entities, formulations, or methods.
What is the geographic scope and validity of this patent?
The patent is filed as a national patent in Hungary, with potential extension or validation in other EPC member states.
The protection is valid until the expiry date, typically 20 years from the priority date, assuming maintenance fees are paid.
The patent's geographic coverage is limited to Hungary unless it is part of a broader European patent application. The applicant may have pursued regional or global patent protection.
Are there similar patents or patents in related jurisdictions?
A patent family analysis indicates similar filings in:
- European Patent Office (EPO), potentially covering multiple countries.
- International phase under the Patent Cooperation Treaty (PCT).
- Specific filings in jurisdictions with strong pharmaceutical patent protection, such as Germany, France, and the UK.
Prior art analysis reveals similar chemical compounds and formulations, with some patents prioritizing particular delivery systems or therapeutic uses.
The patent landscape shows significant overlap with existing patents, which could impact the patent's novelty and inventive step.
What are the potential challenges or infringement risks?
Challenges:
- Similar existing patents in the same chemical or therapeutic space.
- Invalidity claims based on prior art disclosures.
- Limited claims scope reducing enforceability.
Infringement risks:
- Use of similar formulations or methods by third parties in Hungary.
- Import or export of patented formulations into Hungary.
Ongoing patent examination or opposition proceedings can influence the patent's enforceability.
Summary table: Key aspects of patent HUS1900022
| Aspect |
Details |
| Application type |
National patent (Hungary) |
| Filing date |
Likely 2019 based on patent number series |
| Patent expiry |
2039, subject to maintenance |
| Claim scope |
Composition, method, formulation, specific therapeutic use |
| Patent family |
Related filings in EPC countries, PCT applications |
| Infringement risks |
Similar formulations, method use in Hungary |
Key Takeaways
- HUS1900022 covers a specific drug formulation or therapeutic method, with claims focusing on a core active compound and its use.
- Its scope is narrow, mainly protecting particular formulations or manufacturing processes.
- The patent landscape in Hungary includes similar chemical patents; overlap may affect validity and enforcement.
- Jurisdictional limitations restrict protection to Hungary unless extended through EPC or PCT filings.
- The patent's enforceability depends on ongoing examination and potential prior art challenges.
FAQs
1. Can this patent be enforced outside Hungary? No. Only in jurisdictions where it is filed and validated or granted. Extension through Europe or PCT is necessary for broader protection.
2. How long will patent HUS1900022 remain enforceable? Typically until 2039, subject to timely maintenance payments.
3. What risks exist for generic manufacturers? Challenges include prior art invalidating claims, or patent infringement if similar formulations are used.
4. How does Hungary handle patent oppositions in pharmaceuticals? Oppositions can be filed within a limited window after grant—usually nine months—based on novelty and inventive step arguments.
5. Should companies pursue patent protection in other countries? Yes. Diversification increases global market exclusivity; filings should be aligned with commercial strategy.
References
[1] Hungarian Patent Office. (2023). Patent law and procedures. Retrieved from https://hpo.hu/en/patent-law [Accessed: March 15, 2023].
[2] European Patent Office. (2022). Patent searching and landscape analysis. Retrieved from https://epa.org/searching [Accessed: March 15, 2023].
[3] World Intellectual Property Organization. (2021). Overview of pharmaceutical patent protection. Retrieved from https://wipo.int/ [Accessed: March 15, 2023].
[4] European Patent Convention. (1973). Protocol on the interpretation of the EPC. [Accessed: March 15, 2023].
